Roivant to Shutter MDS-Focused ‘Vant’ After Disappointing Phase I/II Trial Results

cafead

Administrator
Staff member
  • cafead   Feb 14, 2024 at 11:12: AM
via Roivant Sciences announced Tuesday during its third-quarter financial report that it will discontinue the development of its investigational SF3B1 modulator RVT-2001, following an interim analysis of a Phase I/II study in myelodysplastic syndromes.

article source